CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL

Blood Adv. 2023 Oct 24;7(20):6320-6324. doi: 10.1182/bloodadvances.2023010461.
No abstract available

MeSH terms

  • Antigens, CD19
  • Burkitt Lymphoma*
  • Child
  • Humans
  • Immunotherapy, Adoptive* / adverse effects
  • Receptors, Antigen, T-Cell
  • T-Lymphocytes

Substances

  • Receptors, Antigen, T-Cell
  • Antigens, CD19